NCT07515807Not yet recruiting
Qatar Cardiometabolic Retrospective Cohort-Analysis Using Artificial Intelligence
Source: ClinicalTrials.gov · Last updated 21 Apr 2026
Brief summary (registry, in English)
Cardiovascular disease is the leading cause of death worldwide, and individuals with diabetes or other cardiometabolic conditions are at increased risk of adverse cardiovascular outcomes. Although advances in prevention and treatment have reduced cardiovascular events globally, cardiometabolic disease continues to represent a significant health burden, particularly in regions with high diabetes prevalence. In Qatar and other Gulf Cooperation Council countries, the prevalence of diabetes and obesity is increasing, contributing to a high proportion of participants presenting with acute coronary syndrome who have type 2 diabetes or prediabetes. This observational study will use electronic medical record data from patients hospitalized at the Heart Hospital with acute coronary syndrome and a concomitant diagnosis of diabetes or prediabetes. The study will assess trends in cardiovascular risk factors and cardiovascular events, including readmission and mortality. An artificial intelligence component will be used to develop and validate machine learning based risk prediction models to forecast adverse cardiovascular outcomes in participants with cardiometabolic disease. These models will integrate clinical, biochemical, imaging, and other non-invasive data routinely collected during participants care to identify predictors of cardiovascular events.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 10000 (estimated)
- First submitted
- 31 Mar 2026
- Start date
- Jul 2026
- Primary completion date
- Jul 2030
- Lead sponsor
- Weill Cornell Medical College in Qatar
- Diseases
- Coronary artery disease, Type 2 diabetes
- NCT number
- NCT07515807
What you commit to
- Study type: Observational
- Planned participants: 10000
- From Jul 2026 to the primary completion date, Jul 2030
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Lab values
- Non-diabetic: HbA1C \< 5.7%
Other
- Non-Qatari or non-Arab participants
- This chart review involves no direct interaction with individuals. Prisoners are not a focus of this study, and incarceration status is not identifiable in the records reviewed.
Who the study is looking for
- Age ≥ 18
- Qatari and Arab participants
- Participants admitted for Acute Coronary Syndrome (ACS) or Acute Heart Failure (AHF)
- Metabolic disease: Diabetes (HbA1C ≥ 6.5% or any HbA1C if a patient is on an antidiabetic agent) or pre-diabetes: 5.7% ≤ HbA1c ≤ 6.4%
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Hamad Medical Corporation Coordinator of this site? Confirm its status | Doha | Qatar | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.